Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA To Advise On Tweaking COVID-19 Vaccines Due To New Variants

Executive Summary

Concerns that new or future mutations of the novel coronavirus may reduce the protection offered by existing COVID-19 vaccines have prompted the European Medicines Agency to develop guidance to help vaccine manufacturers who are planning to alter to their products.

You may also be interested in...



H1 Approvals Seen For Russian, Novavax COVID-19 Vaccines In India

Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.

New Coronavirus Variant May Have Implications For Vaccine Composition

Close monitoring of the effectiveness of coronavirus vaccines will be necessary after a new variant of SARS-CoV-2 was reported to be causing a rapid increase in transmission of the virus in the UK. The pharmaceutical industry says companies are not expecting travel restrictions imposed on the UK to have an impact on the supply of medicines.

US Survey Shows Pharma More Open To Remote Patient Monitoring

COVID-19 is driving changes to how clinical trials are being conducted in the US, with 44% of respondents who participated in a recent survey saying they have adapted or plan to become decentralized in coming months.

Topics

UsernamePublicRestriction

Register

PS143779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel